412
Participants
Start Date
December 12, 2024
Primary Completion Date
January 8, 2029
Study Completion Date
June 9, 2029
fruquintinib
Fruquintinib will be orally administrated once daily for 2 consecutive weeks followed by a 1-week break.
sintilimab
Sintilimab will be intravenously administrated on Day 1 every three weeks.
paclitaxel
175 mg/m\^2 via IV infusion, once a week for 3 weeks followed by a 1-week break.
doxorubicin
60mg/m\^2 via IV infusion, on Day 1 every three weeks.
NOT_YET_RECRUITING
Beijing Obstetrics and Gynecology Hospital, Beijing
NOT_YET_RECRUITING
Harbin Medical University Cancer Hospital, Harbin
RECRUITING
Fudan University Shanghai Cancer Center, Shanghai
NOT_YET_RECRUITING
Shandong Cancer Hospital, Jinan
NOT_YET_RECRUITING
Tianjin Medical University Cancer Institute & Hospital, Tianjin
NOT_YET_RECRUITING
Women's Hospital school of Medical Zhejiang University, Hangzhou
NOT_YET_RECRUITING
Zhejiang Cancer Hospital, Hangzhou
NOT_YET_RECRUITING
The First Affiliated Hospital of Wenzhou Medical University, Wenzhou
NOT_YET_RECRUITING
Fujian Cancer Hospital, Fuzhou
NOT_YET_RECRUITING
Chongqing Cancer Hospital, Chongqing
NOT_YET_RECRUITING
Hunan Cancer Hospital, Changsha
RECRUITING
Henan Cancer Hospital, Zhengzhou
NOT_YET_RECRUITING
SUN Yat-sen University Cancer Center, Guangzhou
RECRUITING
Guangxi Medical University Cancer Hospital, Nanning
NOT_YET_RECRUITING
Yunnan Cancer Hospital, Kunming
NOT_YET_RECRUITING
Xijing Hospital of Air Force Military Medical University, Xi'an
NOT_YET_RECRUITING
Sencond Hospital of Shanxi Medical University, Taiyuan
Lead Sponsor
Hutchmed
INDUSTRY